West Texas Clinical Research | Lubbock, TX

Research site

(Unclaimed)

Location

3809 22nd Street, Suite 2C, Lubbock, Texas, United States of America

Site insights

Top conditions

Top treatments

Upadacitinib

Guselkumab

Adalimumab

Olokizumab

SAR441344

Zasocitinib

ABBV-105

Fasinumab

Deucravacitinib

Ixekizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 18 total trials

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting

Psoriatic Arthritis (PsA)

Biological: Placebo

Biological: Risankizumab

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (STAR)

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by...

Enrolling

Arthritis, Psoriatic

Drug: Placebo

Drug: Guselkumab

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI)

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Active, not recruiting

Crohn Disease

Drug: Guselkumab Dose 3

Drug: Placebo

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).The main aim of the s...

Enrolling

Psoriatic Arthritis

Drug: Active Comparator

Drug: Zasocitinib

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA...

Active, not recruiting

Psoriatic Arthritis

Drug: Apremilast

Drug: Deucravacitinib

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus (APATURA)

This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of...

Enrolling

Systemic Lupus Erythematosus

Drug: SAR441344 SC

Drug: Placebo SC

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent (SOLSTICE)

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate re...

Active, not recruiting

Arthritis, Psoriatic

Drug: Placebo

Drug: Guselkumab

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight (TOGETHER-PsA)

The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at leas...

Active, not recruiting

Obesity

Psoriatic Arthritis

Drug: Tirzepatide

Drug: Ixekizumab

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH)

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how...

Enrolling

Rheumatoid Arthritis

Drug: Adalimumab

Drug: Upadacitinib